Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Forum Financial Management LP

Forum Financial Management LP boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 133.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 114,324 shares of the company's stock after buying an additional 65,399 shares during the quarter. Forum Financial Management LP's holdings in Takeda Pharmaceutical were worth $1,514,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Park Avenue Securities LLC grew its holdings in shares of Takeda Pharmaceutical by 28.3% during the fourth quarter. Park Avenue Securities LLC now owns 27,651 shares of the company's stock valued at $366,000 after purchasing an additional 6,094 shares during the last quarter. DGS Capital Management LLC bought a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $148,000. Blue Trust Inc. grew its holdings in shares of Takeda Pharmaceutical by 27.0% during the fourth quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock valued at $205,000 after purchasing an additional 3,071 shares during the last quarter. Highland Capital Management LLC grew its holdings in shares of Takeda Pharmaceutical by 9.8% during the fourth quarter. Highland Capital Management LLC now owns 67,700 shares of the company's stock valued at $896,000 after purchasing an additional 6,050 shares during the last quarter. Finally, First Affirmative Financial Network grew its holdings in shares of Takeda Pharmaceutical by 29.8% during the fourth quarter. First Affirmative Financial Network now owns 20,602 shares of the company's stock valued at $273,000 after purchasing an additional 4,736 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK traded down $0.08 during trading on Wednesday, hitting $14.59. 1,393,610 shares of the company traded hands, compared to its average volume of 1,930,314. The stock has a market capitalization of $46.42 billion, a price-to-earnings ratio of 36.48, a PEG ratio of 0.24 and a beta of 0.26. The business's fifty day moving average is $14.67 and its 200-day moving average is $14.03. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.